Peter Goadsby, MB BS

Neurologist and headache specialist

Dr. Peter Goadsby, a neurologist, specializes in the diagnosis and treatment of headache disorders, including migraines and cluster headache and other forms of chronic daily headache. He is one of the world's leading headache experts and researchers.

Goadsby came to UCSF from the Institute of Neurology at University College London, National Hospital for Neurology and Neurosurgery and Hospital for Sick Children, Great Ormond Street, London, England. His research focuses on the mechanisms and management of head pain, with a special interest in migraine and trigeminal autonomic cephalalgias. His studies aim to understand the parts of the brain involved in headache and from this to derive new approaches to treatment. He earned a medical degree at the University of New South Wales School of Medicine, completed a residency in neurology at the Prince of Wales Hospital and completed a fellowship in neurology at the National Hospital for Nervous and Mental Diseases in London. He completed post-doctoral work in laboratories in New York and Paris.

Clinics

Headache Center
2330 Post St., Sixth Floor
San Francisco, CA 94115
Phone: (415) 353-8393
Fax: (415) 353-9539

Hours: Monday to Friday
9 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Peter Goadsby

Education

University of New South Wales Doctorate Program, Neurosciences 1983
University of New South Wales School of Medicine 1985

Residencies

Prince Henry, Prince of Wales Hospital, Medicine 1987
Prince Henry, Prince of Wales Hospital, Neurology 1988
Prince Henry, Prince of Wales Hospital, Clinical Neurophysiology 1989

Fellowships

National Hospital for Nervous and Mental Diseases, Neurology 1990

Selected Research and Publications

  1. Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalin OÖ, Faedda N, Lipton RB, Rapoport A, Guidetti V. Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. J Headache Pain. 2017 Nov 29; 18(1):113.
  2. Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalin OÖ, Lipton RB, Rapoport A, Guidetti V. Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. J Headache Pain. 2017 Nov 23; 18(1):109.
  3. Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurol. 2017 Aug 28.
  4. Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19; 89(12):1237-1243.
  5. Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol. 2017 Aug; 19(8):27.
  6. Gelfand AA, Qubty W, Goadsby PJ. Pediatric Migraine Prevention-First, Do No Harm. JAMA Neurol. 2017 Aug 01; 74(8):893-894.
  7. Karsan N, Prabhakar P, Goadsby PJ. Premonitory Symptoms of Migraine in Childhood and Adolescence. Curr Pain Headache Rep. 2017 Jul; 21(7):34.
  8. Bear JJ, Gelfand AA, Goadsby PJ, Bass N. Occipital headaches and neuroimaging in children. Neurology. 2017 Aug 01; 89(5):469-474.
  9. Tso AR, Patniyot IR, Gelfand AA, Goadsby PJ. Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. Neurology. 2017 Jul 18; 89(3):279-283.
  10. Gelfand AA, Qubty W, Patniyot I, Grimes B, Pletcher MJ, Goadsby PJ, Cummings SR. Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial. JAMA Neurol. 2017 Jun 01; 74(6):744-745.
  11. Robbins NM, Goadsby PJ. Author response: Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology. 2017 May 30; 88(22):2156.
  12. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 04; 97(2):553-622.
  13. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017 Mar 20.
  14. Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017 Dec; 18(1):34.
  15. Puledda F, Goadsby PJ. An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine. Headache. 2017 Apr; 57(4):685-691.
  16. Martins-Oliveira M, Akerman S, Holland PR, Hoffmann JR, Tavares I, Goadsby PJ. Neuroendocrine signaling modulates specific neural networks relevant to migraine. Neurobiol Dis. 2017 May; 101:16-26.
  17. Gelfand AA, Johnson H, Lenaerts ME, Litwin JR, De Mesa C, Bogduk N, Goadsby PJ. Neck-Tongue syndrome: A systematic review. Cephalalgia. 2017 Jan 01; 333102416681570.
  18. Zhao Y, Martins-Oliveira M, Akerman S, Goadsby PJ. Comparative effects of traditional Chinese and Western migraine medicines in an animal model of nociceptive trigeminovascular activation. Cephalalgia. 2017 Jan 01; 333102417728245.
  19. Robbins NM, Ito H, Scheinman MM, Goadsby PJ. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology. 2016 Dec 13; 87(24):2522-2526.
  20. Karsan N, Prabhakar P, Goadsby PJ. Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service. J Headache Pain. 2016 Dec; 17(1):94.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.